Harbour BioMed Reports Strong Preclinical Results for AI-Designed Obesity Drug LET003
CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; and SHANGHAI, China, May 18, 2026 Harbour BioMed announced promising preclinical data for LET003, its...
Monoclonal Antibody
Advertisement
Halozyme and GSK Partner on Next-Gen ADC Cancer Therapies
SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...
Mabwell Wins FDA IND Clearance for 9MW5211 in IBD
SHANGHAI, China – May 8, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that...
Eisai and Biogen Receive FDA Extension for LEQEMBI
TOKYO and CAMBRIDGE, Mass., May 8, 2026 Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and...
Cue Biopharma Expands Anti-IgE Pipeline in $691M Deal
Boston, USA | April 30, 2026 Cue Biopharma has entered into a strategic licensing agreement with Ascendant Health Sciences...
Advertisements
Vanda Pharma Publishes Phase III Imsidolimab Data
WASHINGTON, April 28, 2026 Vanda Pharmaceuticals Inc. has announced the publication of pivotal Phase III clinical data evaluating imsidolimab,...
AstraZeneca Saphnelo Pen Gains FDA Approval in US
CAMBRIDGE, UK, April 27, 2026 AstraZeneca has received U.S. Food and Drug Administration (FDA) approval for the subcutaneous self-administration...
Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Biocon Gains Health Canada Nod for Denosumab Biosimilars
Toronto, Canada & Bengaluru, India, April 21, 2026 In a significant advancement for global biosimilars and bone health therapeutics,...
Merck ENFLONSIA Approved in EU for Infant RSV Protection
RAHWAY, N.J., April 17, 2026 Merck & Co., Inc. announced that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab),...
Advertisement
